A neutral risk on the development of new-onset diabetes mellitus (NODM) in Taiwanese patients with dyslipidaemia treated with fibrates

The Scientific World Journal

Volumn 2012, Issue , 2012, Pages

  Lee, Chien Ying ^a,b   Huang, Kuang Hua ^c   Lin, Chun Che ^a,b   Tsai, Tung Han ^c   Shih, Hung Che ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; ANTILIPEMIC AGENT;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW ONSET DIABETES MELLITUS; PRESCRIPTION; RETROSPECTIVE STUDY; RISK FACTOR; TAIWAN; TREATMENT OUTCOME; MIDDLE AGED;

ADULT; DIABETES COMPLICATIONS; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; GEMFIBROZIL; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; TAIWAN;

EID: 84864928988     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/2012/392734     Document Type: Article

References (30)

1. Robins S. J., PPAR ligands and clinical trials: cardiovascular risk reduction with fibrates Journal of Cardiovascular Risk 2001 8 4 195 201 (Pubitemid 32803673)
2. Baigent C., Blackwell L., Emberson J., Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials The Lancet 2010 376 9753 1670 1681
3. Taylor F., Ward K., Moore T. H., Burke M., Davey Smith G., Casas J. P., Ebrahim S., Statins for the primary prevention of cardiovascular disease Cochrane Database of Systematic Reviews 2011 1
4. Sattar N., Preiss D., Murray H. M., Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials The Lancet 2010 375 9716 735 742
5. Sever P. S., Dahlf B., Poulter N. R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S. E., Kristinsson A., McInnes G. T., Mehlsen J., Nieminen M., O'Brien E., stergren J., Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes TrialLipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial The Lancet 2003 361 9364 1149 1158 (Pubitemid 36398384)
6. Heart Protection Study Collaborative Group, MRC/BHF Heart Protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial The Lancet 2002 360 9326 7 22
7. Kjekshus J., Apetrei E., Barrios V., Bhm M., Cleland J. G. F., Cornel J. H., Dunselman P., Fonseca C., Goudev A., Grande P., Gullestad L., Hjalmarson.., Hradec J., Jnosi A., Kamensk G., Komajda M., Korewicki J., Kuusi T., Mach F., Mareev V., McMurray J. J. V., Ranjith N., Schaufelberger M., Vanhaecke J., Van Veldhuisen D. J., Waagstein F., Wedel H., Wikstrand J., Rosuvastatin in older patients with systolic heart failure The New England Journal of Medicine 2007 357 22 2248 2261 (Pubitemid 350190755)
8. Ridker P. M., Danielson E., Fonseca F. A. H., Genest J., Gotto A. M., Kastelein J. J. P., Koenig W., Libby P., Lorenzatti A. J., MacFadyen J. G., Nordestgaard B. G., Shepherd J., Willerson J. T., Glynn R. J., Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein The New England Journal of Medicine 2008 359 21 2195 2207
9. Freeman D. J., Norrie J., Sattar N., Neely R. D. G., Cobbe S. M., Ford I., Isles C., Lorimer A. R., Macfarlane P. W., McKillop J. H., Packard C. J., Shepherd J., Gaw A., Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the west of Scotland coronary prevention study Circulation 2001 103 3 357 362 (Pubitemid 32105973)
10. Keech A., Colquhoun D., Best J., Kirby A., Simes R. J., Hunt D., Hague W., Beller E., Arulchelvam M., Baker J., Tonkin A., Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes of impaired fasting glucose: results from the LIPID trial Diabetes Care 2003 26 10 2713 2721 (Pubitemid 37205536)
11. Forman B. M., Chen J., Evans R. M., Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors and Proceedings of the National Academy of Sciences of the United States of America 1997 94 9 4312 4317 (Pubitemid 27194238)
12. Kliewer S. A., Sundseth S. S., Jones S. A., Brown P. J., Wisely G. B., Koble C. S., Devchand P., Wahli W., Willson T. M., Lenhard J. M., Lehmann J. M., Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors and Proceedings of the National Academy of Sciences of the United States of America 1997 94 9 4318 4323 (Pubitemid 27194239)
13. Fazio S., Linton M. F., The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy Current Atherosclerosis Reports 2004 6 2 148 157
14. Duez H., Lefebvre B., Poulain P., Torra I. P., Percevault F., Luc G., Peters J. M., Gonzalez F. J., Gineste R., Helleboid S., Dzavik V., Fruchart J. C., Fiévet C., Lefebvre P., Staels B., Regulation of human ApoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor modulation Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 3 585 591 (Pubitemid 40315682)
15. Preiss D., Seshasai S. R. K., Welsh P., Murphy S. A., Ho J. E., Waters D. D., DeMicco D. A., Barter P., Cannon C. P., Sabatine M. S., Braunwald E., Kastelein J. J. P., De Lemos J. A., Blazing M. A., Pedersen T. R., Tikkanen M. J., Sattar N., Ray K. K., Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis Journal of the American Medical Association 2011 305 24 2556 2564
16. Berger J. P., Akiyama T. E., Meinke P. T., PPARs: therapeutic targets for metabolic disease Trends in Pharmacological Sciences 2005 26 5 244 251 (Pubitemid 40603072)
17. Lehrke M., Lazar M. A., The many faces of PPAR Cell 2005 123 6 993 999
18. Kersten S., Peroxisome proliferator activated receptors and lipoprotein metabolism PPAR Research 2008
19. Dreyer C., Krey G., Keller H., Control of the peroxisomal -oxidation pathway by a novel family of nuclear hormone receptors Cell 1992 68 5 879 887
20. Zhu Y., Alvares K., Huang Q., Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver Journal of Biological Chemistry 1993 268 36 26817 26820 (Pubitemid 24006385)
21. Saltiel A. R., Olefsky J. M., Thiazolidinediones in the treatment of insulin resistance and type II diabetes Diabetes 1996 45 12 1661 1669 (Pubitemid 26398943)
22. Fujiwara T., Yoshioka S., Yoshioka T., Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats Diabetes 1988 37 11 1549 1558
23. Sarafidis P. A., Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update Fundamental and Clinical Pharmacology 2008 22 3 247 264 (Pubitemid 351712888)
24. Heald M., Cawthorne M. A., Dual acting and Pan-PPAR activators as potential anti-diabetic therapies Handbook of Experimental Pharmacology 2011 203 35 51
25. Wen X., Wang J. S., Backman J. T., Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9 Drug Metabolism and Disposition 2001 29 11 1359 1361 (Pubitemid 33000680)
26. Adkins J. C., Faulds D., Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia Drugs 1997 54 4 615 633 (Pubitemid 27464158)
27. Prueksaritanont T., Richards K. M., Qiu Y., Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes Pharmaceutical Research 2005 22 1 71 78 (Pubitemid 40558148)
28. Bruckert E., De Gennes J. L., Malbecq W., Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia Clinical Cardiology 1995 18 11 621 629 (Pubitemid 26032724)
29. May H. T., Anderson J. L., Pearson R. R., Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study) American Journal of Cardiology 2008 101 4 486 489 (Pubitemid 351199437)
30. Xavier H. T., Drug combinations: statins and fibrates Arquivos Brasileiros de Cardiologia 2005 85 supplement 5 34 35